Determining which patients have hypermutated prostate tumors may have important implications for future precision oncology trials, as mutational burden has been shown to correlate with response to immune checkpoint blockade in several tumor types (e.g. anti-CTLA4, anti-PD1, anti-PDL1) [16–18]. This evidence concerns the gene CTLA4 and neoplasm.